Shots: The NDA is based on two clinical studies, P-III CELESTIAL (XL184-309) & P-II Cabozantinib-2003 study assessing Cabometyx in patients with advanced HCC prior treated with systemic therapy In 2017, […]readmore
Tags : (cabozantinib
Shots: The submission is based on METEOR, CABOSUN and Takeda’s bridging study. METEOR & CABOSUN studies result assessing Cabometyx vs everolimus & sunitinib in patients with RCC + prior treated […]readmore
Regulatory
Exelixis’ Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular
Shots: The approval is based on P-III CELESTIAL study results assessing Cabometyx (60 mg, qd) vs PBO in 760 patients in a ratio (2:1) with 2L advanced HCC who previously […]readmore
Shots: The approval is based on P-III CELESTIAL trial result assessing Cabometyx (60 mg qd) vs PBO in 760 patients in ratio (2:1) with advanced HCC receiving 2L treatment & […]readmore